PMPetra Mazzocchetti

Petra Mazzocchetti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Petra Mazzocchetti has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Paolo Calabresi

    Dipartimento Universitario di Neuroscienze Università Cattolica del Sacro Cuore Rome Italy

    14 shared publications
  • Cinzia Costa

    Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy

    10 shared publications
  • Alessandro Tozzi

    Section of Physiology and Biochemistry, Department of Medicine and Surgery, University of Perugia

    7 shared publications
  • Michela Tantucci

    Neurological Clinic, Department of Medicine Hospital Santa Maria della Misericordia, University of Perugia Perugia Italy

    6 shared publications
  • Valentina Durante

    Neurological Clinic, Department of Medicine, Hospital Santa Maria della Misericordia, University of Perugia, Perugia, Italy

    5 shared publications
  • Alessandro Tozzi

    Department of Experimental Medicine, Section of Physiology and Biochemistry, University of Perugia, Perugia, Italy

    4 shared publications

Latest Publications

  • Open Access

    Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition

    by Petra Mazzocchetti, Andrea Mancini, Miriam Sciaccaluga, Alfredo Megaro, Laura Bellingacci, Massimiliano Di Filippo, Elena Nardi Cesarini, Michele Romoli, Nicolò Carrano, Fabrizio Gardoni, et al.


  • Effects of safinamide on the glutamatergic striatal network in experimental Parkinson’s disease

    by Miriam Sciaccaluga, Petra Mazzocchetti, Guendalina Bastioli, Veronica Ghiglieri, Antonella Cardinale, Paolo Mosci, Carla Caccia, Charlotte Keywood, Elsa Melloni, Gloria Padoani, et al.


  • Top Cited Papers

    Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences

    by Michele Romoli, Petra Mazzocchetti, Renato D'Alonzo, Sabrina Siliquini, Victoria Elisa Rinaldi, Alberto Verrotti, Paolo Calabresi, Cinzia Costa

    After more than a century from its discovery, valproic acid (VPA) still represents one of the most efficient antiepileptic drugs (AEDs). Pre and post-synaptic effects of VPA depend on a very broad spectrum of actions, including the regulation of ionic currents and the facilitation of GABAergic over glutamatergic transmission. As a result, VPA indirectly modulates neurotransmitter release and strengthens the threshold for seizure activity. However, even though participating to the anticonvulsant action, such mechanisms seem to have minor impact on epileptogenesis. Nonetheless, VPA has been reported to exert anti-epileptogenic effects. Epigenetic mechanisms, including histone deacetylases (HDACs), BDNF and GDNF modulation are pivotal to orientate neurons toward a neuroprotective status and promote dendritic spines organization. From such broad spectrum of actions comes constantly enlarging indications for VPA. It represents a drug of choice in child and adult with epilepsy, with either general or focal seizures, and is a consistent and safe IV option in generalized convulsive status epilepticus. Moreover, since VPA modulates DNA transcription through HDACs, recent evidences point to its use as an anti-nociceptive in migraine prophylaxis, and, even more interestingly, as a positive modulator of chemotherapy in cancer treatment. Furthermore, VPA-induced neuroprotection is under investigation for benefit in stroke and traumatic brain injury. Hence, VPA has still got its place in epilepsy, and yet deserves attention for its use far beyond neurological diseases. In this review, we aim to highlight, with a translational intent, the molecular basis and the clinical indications of VPA.


  • Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration

    by Valentina Durante, Antonio de Iure, Vittorio Loffredo, Nishant Vaikath, Maria De Risi, Silvia Paciotti, Ana Quiroga-Varela, Davide Chiasserini, Manuela Mellone, Petra Mazzocchetti, et al.

    Parkinson's disease is a progressive neurodegenerative disorder characterized by altered striatal dopaminergic signalling that leads to motor and cognitive deficits. Parkinson's disease is also characterized by abnormal presence of soluble toxic forms of α-synuclein that, when clustered into Lewy bodies, represents one of the pathological hallmarks of the disease. However, α-synuclein oligomers might also directly affect synaptic transmission and plasticity in Parkinson's disease models. Accordingly, by combining electrophysiological, optogenetic, immunofluorescence, molecular and behavioural analyses, here we report that α-synuclein reduces N-methyl-d-aspartate (NMDA) receptor-mediated synaptic currents and impairs corticostriatal long-term potentiation of striatal spiny projection neurons, of both direct (D1-positive) and indirect (putative D2-positive) pathways. Intrastriatal injections of α-synuclein produce deficits in visuospatial learning associated with reduced function of GluN2A NMDA receptor subunit indicating that this protein selectively targets this subunit both in vitro and ex vivo. Interestingly, this effect is observed in spiny projection neurons activated by optical stimulation of either cortical or thalamic glutamatergic afferents. We also found that treatment of striatal slices with antibodies targeting α-synuclein prevents the α-synuclein-induced loss of long-term potentiation and the reduced synaptic localization of GluN2A NMDA receptor subunit suggesting that this strategy might counteract synaptic dysfunction occurring in Parkinson's disease.


  • Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions

    by Antonio de Iure, Petra Mazzocchetti, Guendalina Bastioli, Barbara Picconi, Cinzia Costa, Ivan Marchionni, Giorgio Casari, Alessandro Tozzi, Daniela Pietrobon, Paolo Calabresi

    Introduction: Familial hemiplegic migraine 2 is a pathology linked to mutation of the ATP1A2 gene producing loss of function of the α2 Na+/K+-ATPase (NKA). W887R/+ knock-in (KI) mice are used to model the familial hemiplegic migraine 2 condition and are characterized by 50% reduced NKA expression in the brain and reduced rate of K+ and glutamate clearance by astrocytes. These alterations might, in turn, produce synaptic changes in synaptic transmission and plasticity. Memory and learning deficits observed in familial hemiplegic migraine patients could be ascribed to a possible alteration of hippocampal neuronal plasticity and measuring possible changes of long-term potentiation in familial hemiplegic migraine 2 KI mice might provide insights to strengthen this link. Results: Here we have investigated synaptic plasticity in distinct hippocampal regions in familial hemiplegic migraine 2 KI mice. We show that the dentate gyrus long-term potentiation of familial hemiplegic migraine 2 mice is abnormally increased in comparison with control animals. Conversely, in the CA1 area, KI and WT mice express long-term potentiation of similar amplitude. Conclusions: The familial hemiplegic migraine 2 KI mice show region-dependent hippocampal plasticity abnormality, which might underlie some of the memory deficits observed in familial migraine.


  • Striatal spreading depolarization: Possible implication in levodopa‐induced dyskinetic‐like behavior

    by Antonio de Iure, Francesco Napolitano, Goichi Beck, Ana Quiroga Varela, Valentina Durante, Miriam Sciaccaluga, Petra Mazzocchetti, Alfredo Megaro, Michela Tantucci, Antonella Cardinale, et al.

    Objective: Spreading depolarization (SD) is a transient self‐propagating wave of neuronal and glial depolarization coupled with large membrane ionic changes and a subsequent depression of neuronal activity. Spreading depolarization in the cortex is implicated in migraine, stroke, and epilepsy. Conversely, spreading depolarization in the striatum, a brain structure deeply involved in motor control and in Parkinson's disease (PD) pathophysiology, has been poorly investigated.Methods: We characterized the participation of glutamatergic and dopaminergic transmission in the induction of striatal spreading depolarization by using a novel approach combining optical imaging, measurements of endogenous DA levels, and pharmacological and molecular analyses.Results: We found that striatal spreading depolarization requires the concomitant activation of D1‐like DA and N‐methyl‐d‐aspartate receptors, and it is reduced in experimental PD. Chronic l‐dopa treatment, inducing dyskinesia in the parkinsonian condition, increases the occurrence and speed of propagation of striatal spreading depolarization, which has a direct impact on one of the signaling pathways downstream from the activation of D1 receptors.Conclusion: Striatal spreading depolarization might contribute to abnormal basal ganglia activity in the dyskinetic condition and represents a possible therapeutic target. © 2019 International Parkinson and Movement Disorder Society


  • Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease

    by Alessandro Tozzi, Valentina Durante, Guendalina Bastioli, Petra Mazzocchetti, Salvatore Novello, Alessandro Mechelli, Michele Morari, Cinzia Costa, Andrea Mancini, Massimiliano Di Filippo, et al.


  • Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis

    by Andrea Mancini, Michela Tantucci, Petra Mazzocchetti, Antonio de Iure, Valentina Durante, Lara Macchioni, Carmela Giampà, Alessandra Alvino, Lorenzo Gaetani, Cinzia Costa, et al.


  • Lacosamide protects striatal and hippocampal neurons from in vitro ischemia without altering physiological synaptic plasticity

    by Petra Mazzocchetti, Michela Tantucci, Guendalina Bastioli, Valeria Calabrese, Massimiliano Di Filippo, Alessandro Tozzi, Paolo Calabresi, Cinzia Costa


  • Open Access

    Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson’s disease

    by Alessandro Tozzi, Michela Tantucci, Saverio Marchi, Petra Mazzocchetti, Michele Morari, Paolo Pinton, Andrea Mancini, Paolo Calabresi

    Parkinson’s disease (PD) is a neurodegenerative disorder in which genetic and environmental factors synergistically lead to loss of midbrain dopamine (DA) neurons. Mutation of leucine-rich repeated kinase2 (Lrrk2) genes is responsible for the majority of inherited familial cases of PD and can also be found in sporadic cases. The pathophysiological role of this kinase has to be fully understood yet. Hyperactivation of Lrrk2 kinase domain might represent a predisposing factor for both enhanced striatal glutamatergic release and mitochondrial vulnerability to environmental factors that are observed in PD. To investigate possible alterations of striatal susceptibility to mitochondrial dysfunction, we performed electrophysiological recordings from the nucleus striatum of a G2019S Lrrk2 mouse model of PD, as well as molecular and morphological analyses of G2019S Lrrk2-expressing SH-SY5Y neuroblastoma cells. In G2019S mice, we found reduced striatal DA levels, according to the hypothesis of alteration of dopaminergic transmission, and increased loss of field potential induced by the mitochondrial complex I inhibitor rotenone. This detrimental effect is reversed by the D2 DA receptor agonist quinpiroleviathe inhibition of the cAMP/PKA intracellular pathway. Analysis of mitochondrial functions in G2019S Lrrk2-expressing SH-SY5Y cells revealed strong rotenone-induced oxidative stress characterized by reduced Ca2+buffering capability and ATP synthesis, production of reactive oxygen species, and increased mitochondrial fragmentation. Importantly, quinpirole was able to prevent all these changes. We suggest that the G2019S-Lrrk2 mutation is a predisposing factor for enhanced striatal susceptibility to mitochondrial dysfunction induced by exposure to mitochondrial environmental toxins and that the D2 receptor stimulation is neuroprotective on mitochondrial function,viathe inhibition of cAMP/PKA intracellular pathway. We suggest new possible neuroprotective strategies for patients carrying this genetic alteration based on drugs specifically targeting Lrrk2 kinase domain and mitochondrial functionality.